

KIRIN R&D DAY 2020 Opening Remarks

October 6, 2020

Yoshinori Isozaki President & CEO Kirin Holdings Company, Limited

KV2027

Long-Term Management Vision "Kirin Group Vision 2027"

Corporate philosophy	KIRIN brings joy to society by crafting food and healthcare products inspired by the blessings of nature and the insights of our customers.			
2027 vision	A global leader in CSV, crea	ating value across our world of Fo	ood & Beverages to Pharmaceutica	
Outcomes	Create economic valu	e (Financial targets), create socia	l value (Non- financial targets)	
Strategy framework	Value creation with Society solving social issues (Health and well-being, community engagement and the environment) Value creation with Consumers by strengthening the bonds between consumers and the brands			
	Organizational	Consumer centric marketing	Technology creating trusted value	
	capabilities for innovation	Diversity and inclusion, culture for innovation	ICT accelerating value creation	
One KIRIN" Values	5	"Passion. Integrity. Diversi	ty.″	

Joy brings us together

KV2027 Long-Term Management Vision "Kirin Group Vision 2027

fer in CSV, creating value across our world of Food & Bey


Overall structure of KV2027

Create new value through solving the social issues


Creating Shared Value



Organizational capabilities for innovation



The Kirin Group has achieved growth by leveraging its core technologies to address unmet needs





Japan Brewery Plant

Manufacturing technology (incl. packaging technology) Engineering technology



The soft drink production line at the Yokohama Plant





Joy brings us together

🍂 KIRIN

Erythropoietin production (roller bottle) system developed by Kirin




ESPO® when it was first released

Fermentation and biotechnology

Research report recommending entry into the pharmaceutical business (1981)

Evolution of our business model — History (2)

Embracing a research-driven spirit founded upon fermentation and biotechnology, we have enhanced our research and development capabilities to search for microorganisms and create cell culture-based production technologies




Joy brings us together

🉈 KIRIN

Kirin Group's core competencies and value creation





marketing expertise


value creation

culture for innovation

Kirin fermentation and biotechnology R&D drawn from 100+ years of experience




Kirin's robust fermentation and biotechnology R&D is world-leading



Kirin Group's Business Domains

Joy brings us together



Part 1

Opening remarks	09:05 – 09:15				
Kirin Holdings Company, Limited Yoshinori Isozaki, President & CEO					
Session 1 R&D at the Kirin Group •Expanding the Kirin Group's technological capabilities and business domains •Technical capabilities to solve social issues	09:15 – 10:05				
Kirin Holdings Company, Limited Noriaki Kobayashi, Director of the Board & Senior Executive Officer (presenter/Q&A)					
Break (10 minutes)					
Session 2 Discovery and Promise of Lactococcus lactis strain Plasma, 10:15 – 11:00 Conversation with Guests •Joint Research and Results of Research on Lactococcus lactis strain Plasma •Potential of Lactococcus lactis strain Plasma					
Yasuhiro Nishizaki, Senior Executive Director, Tokai University Tokyo Hospital Daisuke Fujiwara, Deputy General Manager, Health Science Department, Kirin Holdings Company, Limited					

Part 2

Poster Presentations by the Researchers

11:00 – 12:00



For the first time ever, an Immune System Support Food was registered with Japan's Consumer Affairs Agency (CAA)

The CAA has publicly released a notification of *Foods with Function Claims* With Kirin's 5 of core *L. lactis* strain *Plasma** Products

*Lactococcus lactis strain Plasma

First time an immune system-related product has been registered in Japan



It is now possible to label these products with "Supports maintenance of the immune system in healthy individuals"

A vital step towards becoming a global leader in CSV Contributing to maintaining health of the global community

Part 1

Opening remarks	09:05 – 09:15				
Kirin Holdings Company, Limited Yoshinori Isozaki, President & CEO					
Session 1 R&D at the Kirin Group •Expanding the Kirin Group's technological capabilities and business domains •Technical capabilities to solve social issues	09:15 – 10:05				
Kirin Holdings Company, Limited Noriaki Kobayashi, Director of the Board & Senior Executive Officer (presenter/Q&A)					
Break (10 minutes)					
Session 2 Discovery and Promise of Lactococcus lactis strain Plasma, 10:15 – 11:00 Conversation with Guests •Joint Research and Results of Research on Lactococcus lactis strain Plasma •Potential of Lactococcus lactis strain Plasma					
Yasuhiro Nishizaki, Senior Executive Director, Tokai University Tokyo Hospital Daisuke Fujiwara, Deputy General Manager, Health Science Department, Kirin Holdings Company, Limited					

Part 2

Poster Presentations by the Researchers

11:00 - 12:00



The purpose of a company lies in the solution of social issues.

Societies need companies that can continue to contribute to solving problems, even in the midst of environmental changes that no one could have predicted.

The Kirin Group is committed to CSV management while pursuing sustainable growth, even in the midst of uncertainty and unpredictability

Aim to be a global leader in CSV by solving the issues of the global community while turning the solutions into opportunities for growth This material is intended for informational purposes only and is not a solicitation or offer to buy or sell securities or related financial instruments.

